Panacea Biotec Wins Tax Appeal, ₹329.49 Crore Demand Quashed
Panacea Biotec Limited won a significant tax appeal. The Income Tax Appellate Tribunal (ITAT) quashed assessment orders and deleted disallowances, cancelling a demand of ₹329.49 Crore. This ruling nullifies substantial contingent tax liabilities and potential penalty exposures.
The cancellation of a ₹329.49 Crore demand and deletion of disallowances will have a substantial positive impact on the company's financial position and reduce contingent liabilities.
The company has won a major tax litigation, resulting in the cancellation of a significant demand and deletion of disallowances.
Panacea Biotec Limited has received a significant Order dated February 27, 2026, from the Income Tax Appellate Tribunal (ITAT), New Delhi, received on March 10, 2026. The ITAT has dismissed eight appeals filed by the Deputy Commissioner of Income Tax (DCIT) against orders related to assessment years 2005-06 to 2012-13.
Furthermore, the ITAT allowed two appeals filed by Panacea Biotec against orders concerning assessment years 2010-11 and 2011-12. Crucially, the tribunal quashed the assessment orders passed by the Assessing Officer for assessment years 2005-06 to 2012-13.
This ruling effectively leads to the deletion of all disallowances of expenses and the cancellation of a previously raised demand of ₹329.49 Crore. The company stated that this ruling nullifies substantial contingent tax liabilities and potential penalty exposures.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.